APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral and Injectable Medications for Type 2 Diabetes

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032

23 December 2025115 pages

Choose your research edition.

Industry ResearchOral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral and Injectable Medications for Type 2 Diabetes market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral and Injectable Medications for Type 2 Diabetes include United Laboratories, Yiling Pharmaceutical, Takeda, Tonghua Dongbao, Sanofi, Novo Nordisk, Merck, Eli Lilly and Jiangsu Wanbang, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oral and Injectable Medications for Type 2 Diabetes market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oral and Injectable Medications for Type 2 Diabetes market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral and Injectable Medications for Type 2 Diabetes market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral and Injectable Medications for Type 2 Diabetes.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oral and Injectable Medications for Type 2 Diabetes market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oral and Injectable Medications for Type 2 Diabetes Market by Company

United Laboratories

Yiling Pharmaceutical

Takeda

Tonghua Dongbao

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Wanbang

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

Ganli Pharmaceutical

Beijing Beilu Pharmaceutical

bayer

AstraZeneca

Boehringer Ingelheim

Biocon

Oral and Injectable Medications for Type 2 Diabetes Segment by Type

Insulin

Biguanides

Sulfonylureas

SGLT2 Inhibitors

GLP‑1 Receptor Agonists

DPP‑4 Inhibitors

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Application

Clinic

Hospital

Pharmacy

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral and Injectable Medications for Type 2 Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral and Injectable Medications for Type 2 Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral and Injectable Medications for Type 2 Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral and Injectable Medications for Type 2 Diabetes manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oral and Injectable Medications for Type 2 Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Insulin Table 2. Major Company of Biguanides Table 3. Major Company of Sulfonylureas Table 4. Major Company of SGLT2 Inhibitors Table 5. Major Company of GLP‑1 Receptor Agonists Table 6. Major Company of DPP‑4 Inhibitors Table 7. Major Company of Others Table 8. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 10. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type (2021-2026) Table 11. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 12. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type (2021-2026) Table 13. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2026) & (USD/unit) Table 14. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 15. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type (2027-2032) Table 16. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (US$ Million) Table 17. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type (2027-2032) Table 18. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2027-2032) & (USD/unit) Table 19. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 20. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 22. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 24. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 26. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 28. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (US$ Million) Table 29. Oral and Injectable Medications for Type 2 Diabetes Industry Trends Table 30. Oral and Injectable Medications for Type 2 Diabetes Industry Drivers Table 31. Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges Table 32. Oral and Injectable Medications for Type 2 Diabetes Industry Restraints Table 33. Global Oral and Injectable Medications for Type 2 Diabetes Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Company (2021-2026) Table 35. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Company (2021-2026) & (k units) Table 36. Global Oral and Injectable Medications for Type 2 Diabetes Sales Share by Company (2021-2026) Table 37. Global Oral and Injectable Medications for Type 2 Diabetes Market Price by Company (2021-2026) & (USD/unit) Table 38. Global Oral and Injectable Medications for Type 2 Diabetes Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Oral and Injectable Medications for Type 2 Diabetes Major Company Production Sites and Headquarters Table 40. Global Oral and Injectable Medications for Type 2 Diabetes Company, Product Type & Application Table 41. Global Oral and Injectable Medications for Type 2 Diabetes Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Oral and Injectable Medications for Type 2 Diabetes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (k units) Table 46. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Region (2021-2026) Table 47. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (US$ Million) Table 48. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Region (2021-2026) Table 49. Global Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 50. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032) & (k units) Table 51. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Region (2027-2032) Table 52. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032) & (US$ Million) Table 53. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Region (2027-2032) Table 54. Global Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 55. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 57. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application (2021-2026) Table 58. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 59. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application (2021-2026) Table 60. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2026) & (USD/unit) Table 61. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 62. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application (2027-2032) Table 63. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (US$ Million) Table 64. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application (2027-2032) Table 65. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2027-2032) & (USD/unit) Table 66. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 67. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 69. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 71. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 73. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 75. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (US$ Million) Table 76. United Laboratories Company Information Table 77. United Laboratories Business Overview Table 78. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 80. United Laboratories Recent Development Table 81. Yiling Pharmaceutical Company Information Table 82. Yiling Pharmaceutical Business Overview Table 83. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 85. Yiling Pharmaceutical Recent Development Table 86. Takeda Company Information Table 87. Takeda Business Overview Table 88. Takeda Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 90. Takeda Recent Development Table 91. Tonghua Dongbao Company Information Table 92. Tonghua Dongbao Business Overview Table 93. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 95. Tonghua Dongbao Recent Development Table 96. Sanofi Company Information Table 97. Sanofi Business Overview Table 98. Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 100. Sanofi Recent Development Table 101. Novo Nordisk Company Information Table 102. Novo Nordisk Business Overview Table 103. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 105. Novo Nordisk Recent Development Table 106. Merck Company Information Table 107. Merck Business Overview Table 108. Merck Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 110. Merck Recent Development Table 111. Eli Lilly Company Information Table 112. Eli Lilly Business Overview Table 113. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 115. Eli Lilly Recent Development Table 116. Jiangsu Wanbang Company Information Table 117. Jiangsu Wanbang Business Overview Table 118. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 120. Jiangsu Wanbang Recent Development Table 121. Jiangsu Hengrui Pharmaceuticals Company Information Table 122. Jiangsu Hengrui Pharmaceuticals Business Overview Table 123. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 125. Jiangsu Hengrui Pharmaceuticals Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 130. Pfizer Recent Development Table 131. Beijing Double-Crane Pharmaceutical Company Information Table 132. Beijing Double-Crane Pharmaceutical Business Overview Table 133. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 135. Beijing Double-Crane Pharmaceutical Recent Development Table 136. Huadong Medicine Company Information Table 137. Huadong Medicine Business Overview Table 138. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 140. Huadong Medicine Recent Development Table 141. Ganli Pharmaceutical Company Information Table 142. Ganli Pharmaceutical Business Overview Table 143. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 145. Ganli Pharmaceutical Recent Development Table 146. Beijing Beilu Pharmaceutical Company Information Table 147. Beijing Beilu Pharmaceutical Business Overview Table 148. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 150. Beijing Beilu Pharmaceutical Recent Development Table 151. bayer Company Information Table 152. bayer Business Overview Table 153. bayer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 155. bayer Recent Development Table 156. AstraZeneca Company Information Table 157. AstraZeneca Business Overview Table 158. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 160. AstraZeneca Recent Development Table 161. Boehringer Ingelheim Company Information Table 162. Boehringer Ingelheim Business Overview Table 163. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 165. Boehringer Ingelheim Recent Development Table 166. Biocon Company Information Table 167. Biocon Business Overview Table 168. Biocon Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 170. Biocon Recent Development Table 171. North America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 173. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 174. North America Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (k units) Table 175. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share Forecast by Country (2027-2032) Table 176. North America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026) & (US$ Million) Table 178. North America Oral and Injectable Medications for Type 2 Diabetes Market Share by Country (2021-2026) Table 179. North America Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. North America Oral and Injectable Medications for Type 2 Diabetes Market Share Forecast by Country (2027-2032) Table 181. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 183. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 184. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (k units) Table 185. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share Forecast by Country (2027-2032) Table 186. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026) & (US$ Million) Table 188. Europe Oral and Injectable Medications for Type 2 Diabetes Market Share by Country (2021-2026) Table 189. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Europe Oral and Injectable Medications for Type 2 Diabetes Market Share Forecast by Country (2027-2032) Table 191. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 192. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 193. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 194. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (k units) Table 195. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share Forecast by Country (2027-2032) Table 196. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026) & (US$ Million) Table 198. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Share by Country (2021-2026) Table 199. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Share Forecast by Country (2027-2032) Table 201. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 202. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 203. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 204. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (k units) Table 205. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share Forecast by Country (2027-2032) Table 206. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026) & (US$ Million) Table 208. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Share by Country (2021-2026) Table 209. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Share Forecast by Country (2027-2032) Table 211. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 212. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 213. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 214. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (k units) Table 215. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share Forecast by Country (2027-2032) Table 216. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026) & (US$ Million) Table 218. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Share by Country (2021-2026) Table 219. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Share Forecast by Country (2027-2032) Table 221. Key Raw Materials Table 222. Raw Materials Key Suppliers Table 223. Oral and Injectable Medications for Type 2 Diabetes Distributors List Table 224. Oral and Injectable Medications for Type 2 Diabetes Customers List Table 225. Research Programs/Design for This Report Table 226. Authors List of This Report Table 227. Secondary Sources Table 228. Primary Sources List of Figures Figure 1. Oral and Injectable Medications for Type 2 Diabetes Image Figure 2. Global Oral and Injectable Medications for Type 2 Diabetes Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral and Injectable Medications for Type 2 Diabetes Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032) & (k units) Figure 5. Insulin Image Figure 6. Global Insulin Sales YoY Growth (2021-2032) & (k units) Figure 7. Biguanides Image Figure 8. Global Biguanides Sales YoY Growth (2021-2032) & (k units) Figure 9. Sulfonylureas Image Figure 10. Global Sulfonylureas Sales YoY Growth (2021-2032) & (k units) Figure 11. SGLT2 Inhibitors Image Figure 12. Global SGLT2 Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 13. GLP‑1 Receptor Agonists Image Figure 14. Global GLP‑1 Receptor Agonists Sales YoY Growth (2021-2032) & (k units) Figure 15. DPP‑4 Inhibitors Image Figure 16. Global DPP‑4 Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 19. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Oral and Injectable Medications for Type 2 Diabetes Market Share by Type 2025 VS 2032 Figure 21. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type in 2025 Figure 22. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type in 2025 Figure 23. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type in 2025 Figure 24. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type in 2025 Figure 27. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Oral and Injectable Medications for Type 2 Diabetes Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 35. Hospital Image Figure 36. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 37. Pharmacy Image Figure 38. Global Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 41. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Oral and Injectable Medications for Type 2 Diabetes Market Share by Application 2025 VS 2032 Figure 43. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application in 2025 Figure 44. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application in 2025 Figure 45. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application in 2025 Figure 46. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application in 2025 Figure 49. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share in Value by Application in 2025 Figure 53. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. North America Oral and Injectable Medications for Type 2 Diabetes Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Oral and Injectable Medications for Type 2 Diabetes Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Oral and Injectable Medications for Type 2 Diabetes Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Latin America Oral and Injectable Medications for Type 2 Diabetes Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Oral and Injectable Medications for Type 2 Diabetes Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Oral and Injectable Medications for Type 2 Diabetes Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin
  • Biguanides
  • Sulfonylureas
  • SGLT2 Inhibitors
  • GLP‑1 Receptor Agonists
  • DPP‑4 Inhibitors
  • Others
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • United Laboratories
  • Yiling Pharmaceutical
  • Takeda
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Wanbang
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • Ganli Pharmaceutical
  • Beijing Beilu Pharmaceutical
  • bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oral and Injectable Medications for Type 2 Diabetes Market by Type
  6. 1.3.1 Insulin
  7. 1.3.2 Biguanides
  8. 1.3.3 Sulfonylureas
  9. 1.3.4 SGLT2 Inhibitors
  10. 1.3.5 GLP‑1 Receptor Agonists
  11. 1.3.6 DPP‑4 Inhibitors
  12. 1.3.7 Others
  13. 1.4 Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  14. 1.4.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Oral and Injectable Medications for Type 2 Diabetes Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Oral and Injectable Medications for Type 2 Diabetes Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oral and Injectable Medications for Type 2 Diabetes Industry Trends
  2. 2.2 Oral and Injectable Medications for Type 2 Diabetes Industry Drivers
  3. 2.3 Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges
  4. 2.4 Oral and Injectable Medications for Type 2 Diabetes Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2026)
  2. 3.2 Global Top Players by Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2026)
  3. 3.3 Global Top Players by Oral and Injectable Medications for Type 2 Diabetes Price (2021-2026)
  4. 3.4 Global Oral and Injectable Medications for Type 2 Diabetes Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral and Injectable Medications for Type 2 Diabetes Major Company Production Sites & Headquarters
  6. 3.6 Global Oral and Injectable Medications for Type 2 Diabetes Company, Product Type & Application
  7. 3.7 Global Oral and Injectable Medications for Type 2 Diabetes Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral and Injectable Medications for Type 2 Diabetes Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral and Injectable Medications for Type 2 Diabetes Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral and Injectable Medications for Type 2 Diabetes Tier 1, Tier 2, and Tier 3
4 Oral and Injectable Medications for Type 2 Diabetes Regional Status and Outlook
  1. 4.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oral and Injectable Medications for Type 2 Diabetes Historic Market Size by Region
  3. 4.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oral and Injectable Medications for Type 2 Diabetes Forecasted Market Size by Region
  7. 4.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oral and Injectable Medications for Type 2 Diabetes by Application
  1. 5.1 Oral and Injectable Medications for Type 2 Diabetes Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  7. 5.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 United Laboratories
  2. 6.1.1 United Laboratories Company Information
  3. 6.1.2 United Laboratories Business Overview
  4. 6.1.3 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  6. 6.1.5 United Laboratories Recent Developments
  7. 6.2 Yiling Pharmaceutical
  8. 6.2.1 Yiling Pharmaceutical Company Information
  9. 6.2.2 Yiling Pharmaceutical Business Overview
  10. 6.2.3 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  12. 6.2.5 Yiling Pharmaceutical Recent Developments
  13. 6.3 Takeda
  14. 6.3.1 Takeda Company Information
  15. 6.3.2 Takeda Business Overview
  16. 6.3.3 Takeda Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  18. 6.3.5 Takeda Recent Developments
  19. 6.4 Tonghua Dongbao
  20. 6.4.1 Tonghua Dongbao Company Information
  21. 6.4.2 Tonghua Dongbao Business Overview
  22. 6.4.3 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  24. 6.4.5 Tonghua Dongbao Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Novo Nordisk
  32. 6.6.1 Novo Nordisk Company Information
  33. 6.6.2 Novo Nordisk Business Overview
  34. 6.6.3 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  36. 6.6.5 Novo Nordisk Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Jiangsu Wanbang
  50. 6.9.1 Jiangsu Wanbang Company Information
  51. 6.9.2 Jiangsu Wanbang Business Overview
  52. 6.9.3 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  54. 6.9.5 Jiangsu Wanbang Recent Developments
  55. 6.10 Jiangsu Hengrui Pharmaceuticals
  56. 6.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 6.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 6.10.3 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  60. 6.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Beijing Double-Crane Pharmaceutical
  68. 6.12.1 Beijing Double-Crane Pharmaceutical Company Information
  69. 6.12.2 Beijing Double-Crane Pharmaceutical Business Overview
  70. 6.12.3 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  72. 6.12.5 Beijing Double-Crane Pharmaceutical Recent Developments
  73. 6.13 Huadong Medicine
  74. 6.13.1 Huadong Medicine Company Information
  75. 6.13.2 Huadong Medicine Business Overview
  76. 6.13.3 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  78. 6.13.5 Huadong Medicine Recent Developments
  79. 6.14 Ganli Pharmaceutical
  80. 6.14.1 Ganli Pharmaceutical Company Information
  81. 6.14.2 Ganli Pharmaceutical Business Overview
  82. 6.14.3 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  84. 6.14.5 Ganli Pharmaceutical Recent Developments
  85. 6.15 Beijing Beilu Pharmaceutical
  86. 6.15.1 Beijing Beilu Pharmaceutical Company Information
  87. 6.15.2 Beijing Beilu Pharmaceutical Business Overview
  88. 6.15.3 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  90. 6.15.5 Beijing Beilu Pharmaceutical Recent Developments
  91. 6.16 bayer
  92. 6.16.1 bayer Company Information
  93. 6.16.2 bayer Business Overview
  94. 6.16.3 bayer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  96. 6.16.5 bayer Recent Developments
  97. 6.17 AstraZeneca
  98. 6.17.1 AstraZeneca Company Information
  99. 6.17.2 AstraZeneca Business Overview
  100. 6.17.3 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  102. 6.17.5 AstraZeneca Recent Developments
  103. 6.18 Boehringer Ingelheim
  104. 6.18.1 Boehringer Ingelheim Company Information
  105. 6.18.2 Boehringer Ingelheim Business Overview
  106. 6.18.3 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  108. 6.18.5 Boehringer Ingelheim Recent Developments
  109. 6.19 Biocon
  110. 6.19.1 Biocon Company Information
  111. 6.19.2 Biocon Business Overview
  112. 6.19.3 Biocon Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  114. 6.19.5 Biocon Recent Developments
7 North America by Country
  1. 7.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country
  2. 7.1.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  4. 7.1.3 North America Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  6. 7.2.1 North America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026)
  8. 7.2.3 North America Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country
  2. 8.1.1 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  4. 8.1.3 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  6. 8.2.1 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country
  2. 9.1.1 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  6. 9.2.1 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oral and Injectable Medications for Type 2 Diabetes Sales by Country
  2. 10.1.1 South America Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  4. 10.1.3 South America Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  6. 10.2.1 South America Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026)
  8. 10.2.3 South America Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country
  2. 11.1.1 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  6. 11.2.1 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oral and Injectable Medications for Type 2 Diabetes Value Chain Analysis
  2. 12.1.1 Oral and Injectable Medications for Type 2 Diabetes Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process
  7. 12.2 Oral and Injectable Medications for Type 2 Diabetes Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oral and Injectable Medications for Type 2 Diabetes Distributors
  10. 12.2.3 Oral and Injectable Medications for Type 2 Diabetes Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst